Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.

Capetti AF, Cossu MV, Orofino G, Sterrantino G, Cenderello G, De Socio GV, Cattelan AM, Soria A, Rusconi S, Riccardi N, Baldin GM, Niero FP, Barbarini G, Rizzardini G.

BMC Infect Dis. 2017 Sep 30;17(1):658. doi: 10.1186/s12879-017-2755-4.

2.

Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV.

Capetti AF, Astuti N, Cattaneo D, Rizzardini G.

Expert Opin Drug Metab Toxicol. 2017 Aug 30:1-10. doi: 10.1080/17425255.2017.1361929. [Epub ahead of print]

PMID:
28854832
3.

Morning dosing for dolutegravir-related insomnia and sleep disorders.

Capetti AF, Di Giambenedetto S, Latini A, Sterrantino G, De Benedetto I, Cossu MV, Gori A.

HIV Med. 2017 Aug 1. doi: 10.1111/hiv.12540. [Epub ahead of print] No abstract available.

PMID:
28762661
4.

Correction: Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.

Capetti AF, Sterrantino G, Cossu MV, Cenderello G, Cattelan AM, De Socio GV, Rusconi S, Riccardi N, Baldin GM, Cima S, Niero FP, Rizzardini G, Sasset L.

Antivir Ther. 2017;22(3):273-275. doi: 10.3851/IMP3109. Epub 2016 Nov 28. No abstract available.

PMID:
28400541
5.

Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference.

Gervasoni C, Riva A, Cozzi V, Capetti A, Rizzardini G, Clementi E, Cattaneo D.

J Antimicrob Chemother. 2017 Jun 1;72(6):1842-1844. doi: 10.1093/jac/dkx055. No abstract available.

PMID:
28333266
6.

Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugs: A retrospective study.

Capetti AF, Micale M, Carenzi L, Niero F, Landonio S, Vimercati S, Dedivitiis G, Rizzardini G.

Medicine (Baltimore). 2017 Feb;96(7):e5728. doi: 10.1097/MD.0000000000005728.

7.

Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients.

Borghetti A, Baldin G, Capetti A, Sterrantino G, Rusconi S, Latini A, Giacometti A, Madeddu G, Picarelli C, De Marco R, Cossu MV, Lagi F, Cauda R, De Luca A, Di Giambenedetto S; Odoacre Study Group.

AIDS. 2017 Jan 28;31(3):457-459. doi: 10.1097/QAD.0000000000001357. No abstract available.

PMID:
28079545
8.

Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.

Fiandra L, Capetti A, Sorrentino L, Corsi F.

J Neuroimmune Pharmacol. 2017 Mar;12(1):17-30. doi: 10.1007/s11481-016-9716-3. Epub 2016 Nov 10. Review.

9.

Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides.

Di Biagio A, Riccardi N, Taramasso L, Capetti A, Cenderello G, Signori A, Vitiello P, Guerra M, de Socio GV, Cassola G, Quirino T, Viscoli C.

Int J Antimicrob Agents. 2016 Nov;48(5):551-554. doi: 10.1016/j.ijantimicag.2016.07.009. Epub 2016 Aug 17.

PMID:
27566908
10.

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort.

Capetti AF, Sterrantino G, Cossu MV, Orofino G, Barbarini G, De Socio GV, Di Giambenedetto S, Di Biagio A, Celesia BM, Argenteri B, Rizzardini G.

PLoS One. 2016 Oct 14;11(10):e0164753. doi: 10.1371/journal.pone.0164753. eCollection 2016.

11.

Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.

Capetti AF, Sterrantino G, Cossu MV, Cenderello G, Cattelan AM, De Socio GV, Rusconi S, Riccardi N, Baldin GM, Cima S, Niero FP, Rizzardini G, Sasset L.

Antivir Ther. 2017;22(3):257-262. doi: 10.3851/IMP3095. Epub 2016 Sep 23.

PMID:
27661787
12.

Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.

Galli L, Spagnuolo V, Bigoloni A, D'Arminio Monforte A, Montella F, Antinori A, Di Biagio A, Rusconi S, Guaraldi G, Di Giambenedetto S, Borderi M, Gibellini D, Caramatti G, Lazzarin A, Castagna A; MODAt Study Group.

J Antimicrob Chemother. 2016 Jun;71(6):1637-42. doi: 10.1093/jac/dkw031. Epub 2016 Mar 5.

PMID:
26945711
13.

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CAB, Schmit JC, Wensing AMJ; SPREAD Program, Puchhammer-Stockl E, Sarcletti M, Schmied B, Geit M, Balluch G, Vandamme AM, Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Vandekerckhove LPR, Van den Heuvel A, Van Der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Van Laethem K, Beshkov D, Alexiev I, Lepej SZ, Begovac J, Kostrikis L, Demetriades I, Kousiappa I, Demetriou V, Hezka J, Linka M, Maly M, Machala L, Nielsen C, Jørgensen LB, Gerstoft J, Mathiesen L, Pedersen C, Nielsen H, Laursen A, Kvinesdal B, Liitsola K, Ristola M, Suni J, Sutinen J, Descamps D, Assoumou L, Castor G, Grude M, Flandre P, Storto A, Hamouda O, Kücherer C, Berg T, Braun P, Poggensee G, Däumer M, Eberle J, Heiken H, Kaiser R, Knechten H, Korn K, Müller H, Neifer S, Schmidt B, Walter H, Gunsenheimer-Bartmeyer B, Harrer T, Paraskevis D, Hatzakis A, Zavitsanou A, Vassilakis A, Lazanas M, Chini M, Lioni A, Sakka V, Kourkounti S, Paparizos V, Antoniadou A, Papadopoulos A, Poulakou G, Katsarolis I, Protopapas K, Chryssos G, Drimis S, Gargalianos P, Xylomenos G, Lourida G, Psichogiou M, Daikos GL, Sipsas NV, Kontos A, Gamaletsou MN, Koratzanis G, Sambatakou H, Mariolis H, Skoutelis A, Papastamopoulos V, Georgiou O, Panagopoulos P, Maltezos E, Coughlan S, De Gascun C, Byrne C, Duffy M, Bergin C, Reidy D, Farrell G, Lambert J, O'Connor E, Rochford A, Low J, Coakely P, O'Dea S, Hall W, Mor O, Levi I, Chemtob D, Grossman Z, Zazzi M, de Luca A, Balotta C, Riva C, Mussini C, Caramma I, Capetti A, Colombo MC, Rossi C, Prati F, Tramuto F, Vitale F, Ciccozzi M, Angarano G, Rezza G, Kolupajeva T, Vasins O, Griskevicius A, Lipnickiene V, Schmit JC, Struck D, Sauvageot N, Hemmer R, Arendt V, Michaux C, Staub T, Sequin-Devaux C, Wensing AMJ, Boucher CAB, van de Vijver DAMC, van Kessel A, van Bentum PHM, Brinkman K, Connell BJ, van der Ende ME, Hoepelman IM, van Kasteren M, Kuipers M, Langebeek N, Richter C, Santegoets RMWJ, Schrijnders-Gudde L, Schuurman R, van de Ven BJM, Åsjö B, Kran AB, Ormaasen V, Aavitsland P, Horban A, Stanczak JJ, Stanczak GP, Firlag-Burkacka E, Wiercinska-Drapalo A, Jablonowska E, Maolepsza E, Leszczyszyn-Pynka M, Szata W, Camacho R, Palma C, Borges F, Paixão T, Duque V, Araújo F, Otelea D, Paraschiv S, Tudor AM, Cernat R, Chiriac C, Dumitrescu F, Prisecariu LJ, Stanojevic M, Jevtovic D, Salemovic D, Stanekova D, Habekova M, Chabadová Z, Drobkova T, Bukovinova P, Shunnar A, Truska P, Poljak M, Lunar M, Babic D, Tomazic J, Vidmar L, Vovko T, Karner P, Garcia F, Paredes R, Monge S, Moreno S, Del Amo J, Asensi V, Sirvent JL, de Mendoza C, Delgado R, Gutiérrez F, Berenguer J, Garcia-Bujalance S, Stella N, de Los Santos I, Blanco JR, Dalmau D, Rivero M, Segura F, Elías MJP, Alvarez M, Chueca N, Rodríguez-Martín C, Vidal C, Palomares JC, Viciana I, Viciana P, Cordoba J, Aguilera A, Domingo P, Galindo MJ, Miralles C, Del Pozo MA, Ribera E, Iribarren JA, Ruiz L, de la Torre J, Vidal F, Clotet B, Albert J, Heidarian A, Aperia-Peipke K, Axelsson M, Mild M, Karlsson A, Sönnerborg A, Thalme A, Navér L, Bratt G, Karlsson A, Blaxhult A, Gisslén M, Svennerholm B, Bergbrant I, Björkman P, Säll C, Mellgren Å, Lindholm A, Kuylenstierna N, Montelius R, Azimi F, Johansson B, Carlsson M, Johansson E, Ljungberg B, Ekvall H, Strand A, Mäkitalo S, Öberg S, Holmblad P, Höfer M, Holmberg H, Josefson P, Ryding U.

Clin Infect Dis. 2016 Mar 1;62(5):655-663. doi: 10.1093/cid/civ963. Epub 2015 Nov 29.

14.

Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance.

Capetti A, Cossu MV, Rizzardini G.

Expert Opin Pharmacother. 2015;16(17):2689-702. doi: 10.1517/14656566.2015.1109632. Epub 2015 Nov 27. Review.

PMID:
26612518
15.

Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics.

Calcagno A, Montrucchio C, Capetti A, Guaraldi G, Cenderello G, Calza L, Lanzafame M, Marinaro L, Tettoni MC, Trentini L, D'Avolio A, Di Perri G, Bonora S.

Curr HIV Res. 2016;14(1):54-60.

PMID:
26415700
16.

Nanoformulation of antiretroviral drugs enhances their penetration across the blood brain barrier in mice.

Fiandra L, Colombo M, Mazzucchelli S, Truffi M, Santini B, Allevi R, Nebuloni M, Capetti A, Rizzardini G, Prosperi D, Corsi F.

Nanomedicine. 2015 Aug;11(6):1387-97. doi: 10.1016/j.nano.2015.03.009. Epub 2015 Apr 1.

PMID:
25839392
17.

Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results.

Castagna A, Spagnuolo V, Galli L, Vinci C, Nozza S, Carini E, D'Arminio Monforte A, Montella F, Antinori A, Di Biagio A, Rusconi S, Lazzarin A; MODAt Study Group.

AIDS. 2014 Sep 24;28(15):2269-79. doi: 10.1097/QAD.0000000000000407.

PMID:
25058680
18.

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe.

Frentz D, Van de Vijver DA, Abecasis AB, Albert J, Hamouda O, Jørgensen LB, Kücherer C, Struck D, Schmit JC, Vercauteren J, Åsjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, Coughlan S, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Stanekova D, Stanojevic M, Van Wijngaerden E, Wensing AM, Boucher CA; SPREAD Programme.

BMC Infect Dis. 2014 Jul 21;14:407. doi: 10.1186/1471-2334-14-407.

19.

OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.

Bruno R, Cariti G, Nasta P, Capetti A, Ravasio V, Galli M, Raise E, Palmieri G, Iannacone C, Puoti M.

Liver Int. 2015 Jan;35(1):120-9. doi: 10.1111/liv.12641. Epub 2014 Aug 11.

PMID:
25041136
20.

Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study.

Cattaneo D, Cossu MV, Fucile S, Riva A, Baldelli S, Meraviglia P, Landonio S, Impagnatiello C, Resnati C, Galli M, Clementi E, Capetti A, Rizzardini G, Gervasoni C.

Ther Drug Monit. 2015 Feb;37(1):119-25. doi: 10.1097/FTD.0000000000000114.

PMID:
24988438

Supplemental Content

Loading ...
Support Center